# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EF Hutton analyst Jason Kolbert initiates coverage on Citius Pharma (NASDAQ:CTXR) with a Buy rating and announces Price Targ...
Multiple catalysts for potentially transformative assets in second half of 2024Strong momentum expected from positive topline r...
HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price t...
Management call scheduled for Monday, June 3, 2024 at 8:30 AM ETCRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuti...
Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infecti...